KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Share-based Compensation (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Share-based Compensation for 13 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 3.79% to $14.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.7 million, a 5.9% increase, with the full-year FY2025 number at $53.7 million, up 5.9% from a year prior.
  • Share-based Compensation was $14.1 million for Q4 2025 at Xenon Pharmaceuticals, up from $13.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.7 million in Q2 2024 to a low of $2.0 million in Q1 2021.
  • A 5-year average of $8.4 million and a median of $8.6 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 117.25% in 2022, then dropped 6.82% in 2025.
  • Xenon Pharmaceuticals' Share-based Compensation stood at $2.7 million in 2021, then surged by 114.86% to $5.8 million in 2022, then skyrocketed by 57.98% to $9.2 million in 2023, then skyrocketed by 48.1% to $13.6 million in 2024, then rose by 3.79% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Share-based Compensation are $14.1 million (Q4 2025), $13.7 million (Q3 2025), and $13.7 million (Q2 2025).